Kenya: Landmark Pfizer Cancer Drug Price Cut by Over 7x

• Kenya signed an agreement with Pfizer to cut the price of medicines for several cancers by over seven times.
• The deal, involving KEMSA, covers treatments for breast, stomach, colon, lung, prostate, oesophageal cancers, leukaemia, lymphoma, and multiple myeloma.
• President Ruto stated that a single treatment cycle's cost could drop from Sh1 million to below Sh50,000 in some cases.
• The agreement, part of Pfizer's Accord for a Healthier World, will also enable Kenya to access newer cancer medicines without a 10-year delay.
• Pfizer will make technologies and newer medicines available for local pharmaceutical production in Africa, supporting regional manufacturing capacity.

President Ruto highlighted the profound financial relief this would bring, citing instances where the cost of a single treatment cycle could plummet from as much as Sh1 million to below Sh50,000.

On September 1, a significant agreement was formalized between the Kenyan government and the US pharmaceutical giant Pfizer, poised to dramatically reduce the cost of cancer treatment across the nation. This landmark deal, specifically between Pfizer and the Kenya Medical Supplies Authority (KEMSA), targets a substantial Kenya Pfizer cancer drug price cut, impacting medicines for a range of prevalent cancers. President William Ruto announced that the price of these essential drugs would be slashed by more than seven times, directly addressing a critical barrier to care for countless patients.

The agreement covers treatments for breast, stomach, colon, lung, prostate, and oesophageal cancers, alongside leukaemia, lymphoma, and multiple myeloma. President Ruto highlighted the profound financial relief this would bring, citing instances where the cost of a single treatment cycle could plummet from as much as Sh1 million to below Sh50,000. This development follows a high-level meeting at State House, Nairobi, where President Ruto received Pfizer chairman and chief executive officer Albert Bourla. The discussions also involved key figures including Health Cabinet Secretary Aden Duale, US Embassy Nairobi Charge d’Affaires Susan M Burns, Medical Services Principal Secretary Ouma Oluga, and other Pfizer officials, underscoring the strategic importance of this Ruto Pfizer KEMSA cancer deal.

Beyond immediate cost reductions, this strategic partnership is set to bolster Kenya's broader healthcare objectives, particularly under the framework of the Social Health Authority (SHA). President Ruto emphasized that the substantial Kenya cancer treatment cost reduction achieved through this agreement would render the Sh800,000 cancer package offered by the SHA fully sufficient to cover treatment expenses, eliminating the need for patients to incur additional out-of-pocket costs. This move is a critical step towards realizing the government’s ambition to expand access to specialized healthcare and alleviate the financial burden on patients.

Furthermore, the agreement, established under the Pfizer Accord for a Healthier World Kenya initiative, promises to significantly accelerate access to advanced cancer medicines. President Ruto noted that Kenyan patients would now gain access to newer treatments without the decade-long waiting periods previously experienced. This direct access to cutting-edge therapies is a pivotal component of strengthening the country's Universal Health Coverage programme, ensuring that advanced medical care is not only affordable but also readily available, thereby contributing to a more equitable healthcare system.

The implications of this collaboration extend beyond drug pricing and patient access, signaling a strategic shift towards enhancing local pharmaceutical capabilities across Africa. A key facet of the agreement involves Pfizer making its technologies and newer medicines available for local pharmaceutical production within the continent. President Ruto, who serves as the African Union Champion for Local Manufacturing of Medical Commodities, underscored that this initiative would significantly support efforts to build Africa's capacity to manufacture medicines domestically, thereby reducing reliance on imports.

This commitment aligns with Kenya's broader pharmaceutical pricing policy and its drive to foster self-sufficiency in medical supplies. The government views Pfizer's involvement as a vital contribution to its ongoing health reforms, particularly in ensuring that patients can access advanced medicines without facing financial hardship. President Ruto affirmed the government's continued dedication to collaborating with Pfizer and other partners to strengthen Universal Health Coverage and improve access to affordable treatment, recognizing cancer as a major health and financial challenge that often places care beyond the reach of many households due to the high cost of medicines, diagnostics, and repeated treatment cycles.

This agreement establishes a new benchmark for pharmaceutical pricing and market access for cancer drugs in Kenya, which could influence future regulatory expectations and procurement strategies for other drug manufacturers and healthcare providers. Compliance officers should monitor for related policy shifts concerning local manufacturing incentives and the implementation of the Social Health Authority's cancer package.

Source: Reporting on a Kenyan government and Pfizer agreement